The University of Chicago Header Logo

Connection

Sarosh Rana to Pre-Eclampsia

Back to Details
This is a "connection" page, showing publications Sarosh Rana has written about Pre-Eclampsia.
Sarosh Rana
Connection Strength
24.197
Pre-Eclampsia
  1. Luteolin prevents TNF-a-induced NF-?B activation and ROS production in cultured human placental explants and endothelial cells. Placenta. 2024 Jan; 145:65-71.
    View in: PubMed
    Score: 0.761
  2. Patient and provider perception of home blood pressure monitoring kits. Pregnancy Hypertens. 2023 Dec; 34:33-38.
    View in: PubMed
    Score: 0.752
  3. Angiogenic Biomarkers for Preeclampsia in Clinical Setting: A New Era. Hypertension. 2023 10; 80(10):2029-2032.
    View in: PubMed
    Score: 0.750
  4. Bioflavonoid luteolin prevents sFlt-1 release via HIF-1a inhibition in cultured human placenta. FASEB J. 2023 08; 37(8):e23078.
    View in: PubMed
    Score: 0.743
  5. Reducing the Risk of Term Preeclampsia by Risk-Stratified Timing of Birth: Time to Deliver. Hypertension. 2023 05; 80(5):979-980.
    View in: PubMed
    Score: 0.729
  6. Association of fetal sex with angiogenic factors in normotensive and hypertensive pregnancy states. Pregnancy Hypertens. 2022 Aug; 29:108-115.
    View in: PubMed
    Score: 0.691
  7. Angiogenic Biomarkers for Risk Stratification in Women with Preeclampsia. Clin Chem. 2022 06 01; 68(6):771-781.
    View in: PubMed
    Score: 0.685
  8. Racial Differences in Readmissions in Hypertensive Disorders of Pregnancy. Reprod Sci. 2022 07; 29(7):2071-2078.
    View in: PubMed
    Score: 0.677
  9. Women's perspectives and attitudes towards the utility of angiogenic biomarkers in preeclampsia. Pregnancy Hypertens. 2022 Jun; 28:109-113.
    View in: PubMed
    Score: 0.676
  10. Racial Disparities in Diagnosis, Management, and Outcomes in Preeclampsia. Curr Hypertens Rep. 2022 04; 24(4):87-93.
    View in: PubMed
    Score: 0.674
  11. Prevalence and management of severe intrapartum hypertension in patients with preeclampsia at an urban tertiary care medical center. Pregnancy Hypertens. 2022 Mar; 27:87-93.
    View in: PubMed
    Score: 0.665
  12. Cost effectiveness of the sFlt1/PlGF ratio test as an adjunct to the current practice of evaluating suspected preeclampsia in the United States. Pregnancy Hypertens. 2021 Dec; 26:121-126.
    View in: PubMed
    Score: 0.658
  13. The interval between births and the risk of recurrent preeclampsia among predominantly high risk women in urban tertiary care center. Pregnancy Hypertens. 2021 Aug; 25:7-11.
    View in: PubMed
    Score: 0.637
  14. Real life outpatient biomarker use in management of hypertensive pregnancies in third trimester in a low resource SeTting: ROBUST study. Pregnancy Hypertens. 2021 Mar; 23:97-103.
    View in: PubMed
    Score: 0.618
  15. Imbalances in circulating angiogenic factors in the pathophysiology of preeclampsia and related disorders. Am J Obstet Gynecol. 2022 02; 226(2S):S1019-S1034.
    View in: PubMed
    Score: 0.613
  16. Evaluation of angiogenic factors in the decision to admit women with suspected preeclampsia. Pregnancy Hypertens. 2020 Jul; 21:124-131.
    View in: PubMed
    Score: 0.596
  17. Angiogenic Factor Estimation as a Warning Sign of Preeclampsia-Related Peripartum Morbidity Among Hospitalized Patients. Hypertension. 2019 04; 73(4):868-877.
    View in: PubMed
    Score: 0.550
  18. Preeclampsia: Pathophysiology, Challenges, and Perspectives Circ Res. 2019 03 29; 124(7):1094-1112.
    View in: PubMed
    Score: 0.550
  19. Association of antepartum blood pressure levels and angiogenic profile among women with chronic hypertension. Pregnancy Hypertens. 2018 Oct; 14:110-114.
    View in: PubMed
    Score: 0.529
  20. Angiogenic biomarkers in triage and risk for preeclampsia with severe features. Pregnancy Hypertens. 2018 Jul; 13:100-106.
    View in: PubMed
    Score: 0.519
  21. Abnormal mid-trimester cardiac strain in women with chronic hypertension predates superimposed preeclampsia. Pregnancy Hypertens. 2017 Oct; 10:251-255.
    View in: PubMed
    Score: 0.498
  22. Angiogenic Proteins: Can These Biomarkers Help to Prevent Maternal Deaths Related to Preeclampsia? Hypertension. 2017 03; 69(3):401-403.
    View in: PubMed
    Score: 0.474
  23. Circulating Antiangiogenic Factors and Myocardial Dysfunction in Hypertensive Disorders of Pregnancy. Hypertension. 2016 06; 67(6):1273-80.
    View in: PubMed
    Score: 0.449
  24. KRYPTOR-automated angiogenic factor assays and risk of preeclampsia-related adverse outcomes. Hypertens Pregnancy. 2016 Aug; 35(3):330-45.
    View in: PubMed
    Score: 0.447
  25. Sequential plasma angiogenic factors levels in women with suspected preeclampsia. Am J Obstet Gynecol. 2016 Jul; 215(1):89.e1-89.e10.
    View in: PubMed
    Score: 0.442
  26. Circulating Angiogenic Factors and the Risk of Adverse Outcomes among Haitian Women with Preeclampsia. PLoS One. 2015; 10(5):e0126815.
    View in: PubMed
    Score: 0.420
  27. Modeling risk for severe adverse outcomes using angiogenic factor measurements in women with suspected preterm preeclampsia. Prenat Diagn. 2015 Apr; 35(4):386-93.
    View in: PubMed
    Score: 0.413
  28. Response to Carbillon L et al. letter titled; "The imbalance of circulating angiogenic/anti-angiogenic factors is mild or absent in obese women destined to develop preeclampsia". Hypertens Pregnancy. 2014 Nov; 33(4):525.
    View in: PubMed
    Score: 0.398
  29. Placental lesions of vascular insufficiency are associated with anti-angiogenic state in women with preeclampsia. Hypertens Pregnancy. 2014 Nov; 33(4):427-39.
    View in: PubMed
    Score: 0.398
  30. Angiogenic factors in preeclampsia: potential for diagnosis and treatment. Curr Opin Nephrol Hypertens. 2013 Nov; 22(6):643-50.
    View in: PubMed
    Score: 0.378
  31. Angiogenic factors in diagnosis, management, and research in preeclampsia. Hypertension. 2014 Feb; 63(2):198-202.
    View in: PubMed
    Score: 0.378
  32. Clinical characterization and outcomes of preeclampsia with normal angiogenic profile. Hypertens Pregnancy. 2013 May; 32(2):189-201.
    View in: PubMed
    Score: 0.365
  33. Plasma concentrations of soluble endoglin versus standard evaluation in patients with suspected preeclampsia. PLoS One. 2012; 7(10):e48259.
    View in: PubMed
    Score: 0.352
  34. Circulating lymphangiogenic factors in preeclampsia. Hypertens Pregnancy. 2013; 32(1):42-9.
    View in: PubMed
    Score: 0.349
  35. Circulating angiogenic factors and risk of adverse maternal and perinatal outcomes in twin pregnancies with suspected preeclampsia. Hypertension. 2012 Aug; 60(2):451-8.
    View in: PubMed
    Score: 0.345
  36. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation. 2012 Feb 21; 125(7):911-9.
    View in: PubMed
    Score: 0.334
  37. Placental origins of angiogenic dysfunction in mirror syndrome. Hypertens Pregnancy. 2012; 31(2):211-7.
    View in: PubMed
    Score: 0.332
  38. Physicians' knowledge of future vascular disease in women with preeclampsia. Hypertens Pregnancy. 2012; 31(1):50-8.
    View in: PubMed
    Score: 0.314
  39. Abnormal placentation, angiogenic factors, and the pathogenesis of preeclampsia. Obstet Gynecol Clin North Am. 2010 Jun; 37(2):239-53.
    View in: PubMed
    Score: 0.298
  40. Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension. 2007 Jul; 50(1):137-42.
    View in: PubMed
    Score: 0.242
  41. Cytomegalovirus-induced mirror syndrome associated with elevated levels of circulating antiangiogenic factors. Obstet Gynecol. 2007 Feb; 109(2 Pt2):549-52.
    View in: PubMed
    Score: 0.237
  42. Neuropsychological performance in normal pregnancy and preeclampsia. Am J Obstet Gynecol. 2006 Jul; 195(1):186-91.
    View in: PubMed
    Score: 0.223
  43. Association of activin A and postpartum blood pressure in peripartum cardiomyopathy. Pregnancy Hypertens. 2023 Dec; 34:60-66.
    View in: PubMed
    Score: 0.188
  44. Circulating Angiogenic Factor Levels in Hypertensive Disorders of Pregnancy. NEJM Evid. 2022 Dec; 1(12):EVIDoa2200161.
    View in: PubMed
    Score: 0.177
  45. The additive role of angiogenic markers for women with confirmed preeclampsia. Am J Obstet Gynecol. 2023 05; 228(5):573.e1-573.e11.
    View in: PubMed
    Score: 0.177
  46. Clinical interpretation and implementation of the sFlt-1/PlGF ratio in the prediction, diagnosis and management of preeclampsia. Pregnancy Hypertens. 2022 Mar; 27:42-50.
    View in: PubMed
    Score: 0.166
  47. Is Prolonging Gestation in Preeclampsia For Better or Worse in Preventing Cardiovascular Disease? Hypertension. 2021 11; 78(5):1395-1397.
    View in: PubMed
    Score: 0.164
  48. The 2021 International Society for the Study of Hypertension in Pregnancy classification, diagnosis & management recommendations for international practice. Pregnancy Hypertens. 2022 Mar; 27:148-169.
    View in: PubMed
    Score: 0.164
  49. Angiogenic factors and prediction for ischemic placental disease in future pregnancies. Pregnancy Hypertens. 2021 Aug; 25:12-17.
    View in: PubMed
    Score: 0.159
  50. Long-Term Postpartum Cardiac Function and Its Association With Preeclampsia. J Am Heart Assoc. 2021 02; 10(5):e018526.
    View in: PubMed
    Score: 0.157
  51. Antepartum Aspirin Administration Reduces Activin A and Cardiac Global Longitudinal Strain in Preeclamptic Women. J Am Heart Assoc. 2020 06 16; 9(12):e015997.
    View in: PubMed
    Score: 0.149
  52. Analytical validation of soluble fms-like tyrosine and placental growth factor assays on B·R·A·H·M·S KRYPTOR Compact Plus automated immunoassay platform. Pregnancy Hypertens. 2018 Jan; 11:66-70.
    View in: PubMed
    Score: 0.126
  53. Gelsolin is an endogenous inhibitor of syncytiotrophoblast extracellular vesicle shedding in pregnancy. Pregnancy Hypertens. 2016 Oct; 6(4):333-339.
    View in: PubMed
    Score: 0.114
  54. Trophoblast mitochondrial function is impaired in preeclampsia and correlates negatively with the expression of soluble fms-like tyrosine kinase 1. Pregnancy Hypertens. 2016 Oct; 6(4):313-319.
    View in: PubMed
    Score: 0.114
  55. Angiogenic factor imbalance early in pregnancy predicts adverse outcomes in patients with lupus and antiphospholipid antibodies: results of the PROMISSE study. Am J Obstet Gynecol. 2016 Jan; 214(1):108.e1-108.e14.
    View in: PubMed
    Score: 0.108
  56. Epidemiology and Mechanisms of De Novo and Persistent Hypertension in the Postpartum Period. Circulation. 2015 Nov 03; 132(18):1726-33.
    View in: PubMed
    Score: 0.108
  57. The association of circulating angiogenic factors and HbA1c with the risk of preeclampsia in women with preexisting diabetes. Hypertens Pregnancy. 2014 Feb; 33(1):81-92.
    View in: PubMed
    Score: 0.095
  58. Relationship between nulliparity and preeclampsia may be explained by altered circulating soluble fms-like tyrosine kinase 1. Hypertens Pregnancy. 2014 May; 33(2):250-9.
    View in: PubMed
    Score: 0.095
  59. The course of angiogenic factors in early- vs. late-onset preeclampsia and HELLP syndrome. J Perinat Med. 2013 Sep 01; 41(5):511-6.
    View in: PubMed
    Score: 0.093
  60. Subclinical left ventricular dysfunction in preeclamptic women with preserved left ventricular ejection fraction: a 2D speckle-tracking imaging study. Circ Cardiovasc Imaging. 2012 Nov; 5(6):734-9.
    View in: PubMed
    Score: 0.087
  61. Transcriptionally active syncytial aggregates in the maternal circulation may contribute to circulating soluble fms-like tyrosine kinase 1 in preeclampsia. Hypertension. 2012 Feb; 59(2):256-64.
    View in: PubMed
    Score: 0.083
  62. Preeclampsia and the risk of large-for-gestational-age infants. Am J Obstet Gynecol. 2011 May; 204(5):425.e1-6.
    View in: PubMed
    Score: 0.079
  63. First trimester vitamin D, vitamin D binding protein, and subsequent preeclampsia. Hypertension. 2010 Oct; 56(4):758-63.
    View in: PubMed
    Score: 0.076
  64. Preeclampsia: the role of angiogenic factors in its pathogenesis. Physiology (Bethesda). 2009 Jun; 24:147-58.
    View in: PubMed
    Score: 0.070
  65. Circulating soluble endoglin and placental abruption. Prenat Diagn. 2008 Sep; 28(9):852-8.
    View in: PubMed
    Score: 0.066
  66. Use of circulating antiangiogenic factors to differentiate other hypertensive disorders from preeclampsia in a pregnant woman on dialysis. Am J Kidney Dis. 2008 Jun; 51(6):1029-32.
    View in: PubMed
    Score: 0.065
  67. Circulating levels of the antiangiogenic marker soluble FMS-like tyrosine kinase 1 are elevated in women with pregestational diabetes and preeclampsia: angiogenic markers in preeclampsia and preexisting diabetes. Diabetes Care. 2007 Feb; 30(2):375-7.
    View in: PubMed
    Score: 0.059
  68. Luteolin-induced vasorelaxation in uterine arteries from normal pregnant rats. Pregnancy Hypertens. 2021 Mar; 23:11-17.
    View in: PubMed
    Score: 0.038
  69. Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature. 2012 May 09; 485(7398):333-8.
    View in: PubMed
    Score: 0.021
  70. Mid-pregnancy levels of angiogenic markers as indicators of pathways to preterm delivery. J Matern Fetal Neonatal Med. 2012 Jul; 25(7):1135-41.
    View in: PubMed
    Score: 0.021
  71. Role of oxidative stress and antioxidant supplementation in pregnancy disorders. Am J Clin Nutr. 2011 Dec; 94(6 Suppl):1980S-1985S.
    View in: PubMed
    Score: 0.020
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.